Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics
Kajal B Larson, Jennifer R King, Edward P Acosta Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL, USA Abstract: Raltegravir was the first HIV integrase strand-transfer inhibitor to be approved by the US FDA, in October 2007, for the treatment of HIV-1 i...
Saved in:
Main Authors: | Larson KB (Author), King JR (Author), Acosta EP (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2013-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical utility of raltegravir for the treatment of HIV infection in children and adolescents
by: Nuttall J, et al.
Published: (2013) -
Raltegravir in the management of HIV-infected patients
by: Hans-Jürgen Stellbrink
Published: (2008) -
Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing
by: Jos Lommerse, et al.
Published: (2019) -
Raltegravir: first in class HIV integrase inhibitor
by: Zelalem Temesgen, et al.
Published: (2008) -
ASSESSMENT OF ECONOMIC EFFICIENCY OF APPLICATION OF RALTEGRAVIR BY PATIENTS WITHOUT EXPERIENCE OF TYPE 1 HIV INFECTION THERAPY IN RUSSIA
by: Elamin H. Elbasha, et al.
Published: (2015)